Vedolizumab Quantitation with Antibodies, Serum
Also known as: VEDOL AB
Use
This test is used to evaluate response failure to vedolizumab therapy and to adjust dosage appropriately. It is particularly applicable for patients undergoing treatment for conditions such as inflammatory bowel disease (IBD) where monitoring drug levels and antibody presence is crucial for optimal therapeutic efficacy.
Special Instructions
Patients must discontinue multivitamins or dietary supplements containing biotin (vitamin B7), as well as nivolumab (Opdivo), prior to specimen collection to avoid interference with test results. Specimen should be collected immediately before the next scheduled dosing as a trough specimen.
Limitations
The test was developed and its performance characteristics determined by Mayo Clinic Laboratories in a manner consistent with CLIA requirements. However, it has not been cleared or approved by the U.S. Food and Drug Administration, which may affect its usage in certain regulatory environments.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 59462-2
- 86899-2
- 90805-3
Result Turnaround Time
8-14 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1.5 mL
Minimum Volume
0.75 mL
Container
Plain red or serum separator tube (SST).
Collection Instructions
Collect specimen immediately before the next scheduled dose (trough specimen).
Patient Preparation
12 hours prior to specimen collection discontinue multivitamins or dietary supplements containing biotin (vitamin B7), commonly found in hair, skin, and nail supplements. Nivolumab (Opdivo) must be discontinued at least 4 weeks prior to testing.
Storage Instructions
Refrigerated; also acceptable: frozen.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 28 days |
| Frozen | 28 days |